Kaempferol

Promising preclinical profile but very limited human clinical data for isolated kaempferol supplementation. Dietary intake is associated with health benefits in epidemiological studies.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Epidemiological studies associate higher dietary kaempferol intake with reduced cardiovascular and cancer risk. Preclinical studies show anti-inflammatory, antioxidant, and pro-apoptotic activity. However, oral bioavailability is low, and human trials with isolated kaempferol are essentially absent.

• Anti-inflammatory and antioxidant in preclinical models
• Epidemiological association with reduced cardiovascular risk
• Preclinical anticancer properties

No established supplemental dose. Dietary intake from food sources averages 5-20 mg daily.

• Limited data on isolated supplementation
• Generally considered safe from dietary sources

Limited safety data for isolated supplementation. May interact with CYP enzymes at high doses.

Nearly all evidence is epidemiological or preclinical. Bioavailability of isolated kaempferol is poor. Benefits from whole foods may involve synergy with other phytochemicals.

• Longevity25
• Immunity22